COMPASS: Net Clinical Benefit of Extended Dual Pathway Inhibition in Chronic Coronary Syndrome as Classified by the 2024 ESC Criteria: a COMPASS Substudy
- Homepage
- >
- Publications
- >
- COMPASS: Net Clinical Benefit of Extended Dual Pathway Inhibition in Chronic Coronary Syndrome as Classified by the 2024 ESC Criteria: a COMPASS Substudy
